JANUX THERAPEUTICS INC (JANX)
US47103J1051 - Common Stock
Overall JANX gets a fundamental rating of 4 out of 10. We evaluated JANX against 561 industry peers in the Biotechnology industry. JANX has a great financial health rating, but its profitability evaluates not so good. JANX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
JANX had negative earnings in the past year.
In the past year JANX has reported a negative cash flow from operations.
JANX had negative earnings in each of the past 5 years.
JANX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
JANX has a better Return On Assets (-8.71%) than 87.93% of its industry peers.
JANX's Return On Equity of -9.23% is amongst the best of the industry. JANX outperforms 90.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.71% | ||
| ROE | -9.23% | ||
| ROIC | N/A |
ROA(3y)-13.75%
ROA(5y)-130.91%
ROE(3y)-15.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for JANX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
JANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
JANX has more shares outstanding than it did 1 year ago.
JANX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 45.47 indicates that JANX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 45.47, JANX belongs to the best of the industry, outperforming 98.02% of the companies in the same industry.
JANX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 45.47 |
ROIC/WACCN/A
WACC10.67%
2.3 Liquidity
JANX has a Current Ratio of 38.80. This indicates that JANX is financially healthy and has no problem in meeting its short term obligations.
JANX's Current ratio of 38.80 is amongst the best of the industry. JANX outperforms 99.28% of its industry peers.
A Quick Ratio of 38.80 indicates that JANX has no problem at all paying its short term obligations.
JANX's Quick ratio of 38.80 is amongst the best of the industry. JANX outperforms 99.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 38.8 | ||
| Quick Ratio | 38.8 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 20.95% over the past year.
JANX shows a strong growth in Revenue. In the last year, the Revenue has grown by 53.88%.
EPS 1Y (TTM)20.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-104%
Revenue 1Y (TTM)53.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-82.56%
3.2 Future
The Earnings Per Share is expected to decrease by -18.89% on average over the next years. This is quite bad
JANX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 69.04% yearly.
EPS Next Y-2.28%
EPS Next 2Y-22.77%
EPS Next 3Y-24.88%
EPS Next 5Y-18.89%
Revenue Next Year74.89%
Revenue Next 2Y-27.37%
Revenue Next 3Y7.96%
Revenue Next 5Y69.04%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for JANX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JANX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
JANX's earnings are expected to decrease with -24.88% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.77%
EPS Next 3Y-24.88%
5. Dividend
5.1 Amount
JANX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
JANUX THERAPEUTICS INC
NASDAQ:JANX (1/8/2025, 8:10:56 PM)
Premarket: 50.0014 -0.82 (-1.61%)50.82
-6.99 (-12.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.96%
Inst Owner Change0%
Ins Owners1.85%
Ins Owner Change-15.6%
Market Cap2.93B
Analysts86
Price Target90.59 (78.26%)
Short Float %12.26%
Short Ratio6.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.53%
Min EPS beat(2)-52.65%
Max EPS beat(2)65.71%
EPS beat(4)3
Avg EPS beat(4)15.47%
Min EPS beat(4)-52.65%
Max EPS beat(4)65.71%
EPS beat(8)7
Avg EPS beat(8)20.98%
EPS beat(12)9
Avg EPS beat(12)15.71%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)481.4%
Min Revenue beat(2)-73.78%
Max Revenue beat(2)1036.58%
Revenue beat(4)3
Avg Revenue beat(4)312.49%
Min Revenue beat(4)-73.78%
Max Revenue beat(4)1036.58%
Revenue beat(8)7
Avg Revenue beat(8)238.95%
Revenue beat(12)11
Avg Revenue beat(12)215.15%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25.69%
PT rev (3m)31.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-18.99%
EPS NY rev (1m)-0.11%
EPS NY rev (3m)-18.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-66.85%
Revenue NY rev (1m)1.91%
Revenue NY rev (3m)-5.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 224.56 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.47 | ||
| P/tB | 4.47 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.17
EYN/A
EPS(NY)-2.02
Fwd EYN/A
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS0.23
BVpS11.38
TBVpS11.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.71% | ||
| ROE | -9.23% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-13.75%
ROA(5y)-130.91%
ROE(3y)-15.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 39.7% | ||
| Cap/Sales | 6.34% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 38.8 | ||
| Quick Ratio | 38.8 | ||
| Altman-Z | 45.47 |
F-Score5
WACC10.67%
ROIC/WACCN/A
Cap/Depr(3y)735.98%
Cap/Depr(5y)441.59%
Cap/Sales(3y)46.15%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-104%
EPS Next Y-2.28%
EPS Next 2Y-22.77%
EPS Next 3Y-24.88%
EPS Next 5Y-18.89%
Revenue 1Y (TTM)53.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-82.56%
Revenue Next Year74.89%
Revenue Next 2Y-27.37%
Revenue Next 3Y7.96%
Revenue Next 5Y69.04%
EBIT growth 1Y-14.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.73%
EBIT Next 3Y-24.45%
EBIT Next 5YN/A
FCF growth 1Y19.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.84%
OCF growth 3YN/A
OCF growth 5YN/A